Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 196 participants.

Also called NCT07713914

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 196 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07713914
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07713914. Randomized; no masking; primary purpose treatment. Start 2026-07-22 (anticipated); primary completion 2028-07-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension
Acronym
ASCEND-PAH
Condition
Pulmonary Arterial Hypertension (PAH)
Intervention (Drug)
Prostacyclin Pathway Agent
Intervention (Drug)
Sildenafil Dose Optimization
Lead sponsor
University of Sao Paulo General Hospital (class: other)

Record details

Record id
cardio:ct-nct07713914
Content hash
dac95219f4bacf38cc32901c49566facaefdb972e4fd36ae9439acecead50fdf